Physician profile
Stephen Arthur Stack
NPI 1316985146
$12,247.44
in general payments reported to CMS, 2019-2025
51 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,922 · 2020: $1,481 · 2021: $1,698 · 2022: $1,767 · 2023: $2,026 · 2024: $1,616 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,346 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.22 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,726.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,372.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,294.99 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $857.32 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $827.86 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $677.26 | 2019-2025 | Jardiance |
| Pfizer INC. | $608.65 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $512.24 | 2019-2024 | |
| Amgen INC. | $416.67 | 2019-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $313.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $299.05 | 2021-2025 | |
| Gilead Sciences, INC. | $285.81 | 2019-2025 | |
| Exact Sciences Corporation | $261.45 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $255.93 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.00 | 2019-2025 | Xifaxan, Cycloset |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Stack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.